Drilldown: Medicines

Other values:

Search

None (42) · Adderall, Adderall XR, Mydayis (1) · Captagon (1) · Desoxyn (1) · Dexedrine (1) · DXM (1) · DXO (1) · Focalin, Focalin XR (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) · Ritalin, Ritalin LA, Concerta, Metadate CD, Daytrana, Quillivant XR (1) · Spravato (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

None (1) · 5-HT2A agonist (12) · 5-HT2A agonist; long duration (1) · 5-HT2A agonist; MAO inhibitor (1) · 5-HT2A agonist; milder than other 2C-x (1) · 5-HT2A partial agonist (1) · Active metabolite of DXM; NMDA antagonist (1) · Contains salvinorin A (1) · Extremely potent 5-HT2A agonist; vasoconstrictor (1) · Extremely potent 5-HT2A agonist; very long duration (1) · Kappa-opioid agonist; NMDA antagonist; SERT/DAT/NET inhibitor (1) · Kappa-opioid receptor agonist (1) · Monoamine releasing agent (1) · Monoamine releasing agent, TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport (1) · NMDA antagonist (3) · NMDA antagonist; endogenous opioid releaser (1) · NMDA antagonist; fluorinated ketamine analogue (1) · NMDA antagonist; kappa-opioid agonist (1) · NMDA antagonist; ketamine analogue (1) · NMDA antagonist; more stimulating than PCP (1) · NMDA antagonist; opioid agonist (1) · NMDA antagonist; potent opioid agonist (1) · NMDA antagonist; SERT inhibitor; sigma-1 agonist (1) · NMDA antagonist; sigma receptor agonist (2) · NMDA antagonist; sigma receptor agonist; dopaminergic (1) · NMDA antagonist; sigma-1 agonist; serotonin reuptake inhibitor (1) · Norepinephrine–dopamine reuptake inhibition (DAT, NET) (1) · Norepinephrine–dopamine reuptake inhibition (DAT, NET), d-threo enantiomer of methylphenidate (1) · Potent 5-HT2A agonist (5) · Potent 5-HT2A agonist; no oral activity (1) · Potent 5-HT2A agonist; very long duration (1) · Prodrug of amphetamine + theophylline (1) · TAAR1 agonism, VMAT2 substrate, DAT/NET reverse transport, net release of dopamine and norepinephrine (1) · Very potent 5-HT2A agonist; long duration (1)

None (47) · ADHD, narcolepsy (1) · Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1) · '"`UNIQ--vote-00000150-QINU`"', '"`UNIQ--vote-00000151-QINU`"' (1) · '"`UNIQ--vote-000004B9-QINU`"', '"`UNIQ--vote-000004BA-QINU`"', '"`UNIQ--vote-000004BB-QINU`"' (1) · '"`UNIQ--vote-00000562-QINU`"', '"`UNIQ--vote-00000563-QINU`"', '"`UNIQ--vote-00000564-QINU`"', '"`UNIQ--vote-00000565-QINU`"', '"`UNIQ--vote-00000566-QINU`"' (1)

None (49) · 2.5 mg IR, 5 mg XR, or 12.5mg Mydayis (1) · 5 mg PO (1) · Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1)

None (49) · 28 mg/device (each dose uses 2 devices) (1) · Desoxyn 5 mg tabs (1) · IR tabs 5, 7.5, 10, 12.5, 15, 20, 30 mg; XR caps 5, 10, 15, 20, 25, 30 mg; Mydayis caps 12.5, 25, 37.5, 50 mg (1)

None (49) · 25 mg/day (ADHD per Desoxyn label); 15 mg/day (obesity, short-term, per Desoxyn label) (1) · 84 mg per session (1) · XR = 40 or 60 mg/d; IR = 40 or 60 mg/d'"`UNIQ--ref-00000567-QINU`"' (1)

None (46) · insufflated (1) · Intranasal (under direct medical supervision) (1) · Oral (4) · Oral (prescribed) (1) · PR (1) · transdermal (1)

None (47) · 20–60 min (oral) (1) · 30–60 min (1) · 45-75 min (oral) (1) · IR: 30–60 min; XR: 1–2 h to peak effect (1) · Within hours of first administration (1)

None (47) · 4-8 h (1) · Acute effect ~24 hours; cumulative effect builds with repeated dosing (1) · IR 3–5 h; LA/SR 6–8 h; Concerta 10–12 h; Daytrana ~9 h wear time (1) · IR 4–6 h; XR 10–12 h; Mydayis 14–16 h (1) · IR 4–6 h; XR 8–12 h (1)

None (47) · 2.2 h (IR parent); ~3 h (XR parent) (1) · 2–3 h (parent compound) (1) · D-amphetamine ~10 h; L-amphetamine ~13 h (adults) (1) · Not well characterized (1) · ~7-12 hours (1)

None (47) · Not well characterized (1) · ~22–25% (1) · ~30% (high first-pass) (1) · ~48% intranasal (1) · ~75–90% (oral) (1)

None (46) · Avoid; may cause fetal harm (1) · Category C (2) · Category C (per Desoxyn label) (1) · Not established (1) · Pregnancy categories were retired by FDA in 2015. Limited reproductive data with small observational signal for cardiac malformations; risk-benefit decision, with many patients deferring ADHD treatment during pregnancy. See pregnancy_details for the full discussion. (1)

None (46) · Rx, Schedule III (US). REMS program required. (1) · Schedule II (4) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1)